Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACBETH: Aflibercept in wAMD non-responders
NCT01896284Phase 4Completed
- Sponsor
- Barcelona Macula Foundation
- Start
- Jul 2013
- Primary completion
- Nov 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Barcelona Macula Foundation. Started Jul 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01896284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896284.